Eastern Ablation Registry for Solid Tumor (EAST) (EAST)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03362749|
Recruitment Status : Unknown
Verified April 2017 by National Taiwan University Hospital.
Recruitment status was: Recruiting
First Posted : December 5, 2017
Last Update Posted : December 5, 2017
|Condition or disease||Intervention/treatment|
|Solid Tumor Including Thyroid, Bone, Liver, Pancreas||Other: RFA, MWA, cryo and IRE|
Local tumor ablation is among the major anti-tumor modalities worldwide. Although surgical resection is potentially curative and beneficial to long-term patient survival, the majority of patients are deemed unresectable.
In 2003, the International Working Group on Image-Guided Tumor Ablation published a document titled "Image-Guided Tumor Ablation: Proposal for Standardization of Terms and Reporting Criteria". Ten years later, the field of tumor ablation continues to evolve. Tumor ablation modalities that were still being developed at the time of original preparation, such as microwave, irreversible electroporation (IRE), have been introduced and clinical niches are being defined. Preliminary clinical studies have matured into larger longer-term series with 5- and 10-year follow-up data on par with the surgical and medical oncology literature. Over the interim, our initial document has also given rise to several additional position statements within the field of interventional oncology and been the source for more focused societal statements on tumor ablation of liver, kidney, pancreas and musculoskeletal tumors.
Given the number of changes that have taken place in the field of tumor ablation in the past 10 years, it is our intention to ensure that this highly utilized standardization continues to remain relevant as it unites all investigators and clinicians practicing interventional oncology by providing a common language to describe therapies and outcomes, develop studies, and communicate with other medical specialties. In an attempt to attain greater Asian-wide adoption, the investigators will initiate the registry system for local tumor ablation in Taiwan, China, Korea, Singapore, Hong Kong and Thailand.
The main objective of the registry will be "improved precision and communication in this field that leads to more accurate comparison of technologies and results and ultimately to improved patient outcomes". This study aims to establish a local tumor ablation registry in Taiwan and collect real-life data regarding the safety, efficacy, changes in clinical presentation, and practice pattern of treatment in patients with clinically confirmed solid tumor including thyroid, bone, liver, pancreas and those which are scheduated to be treated by local tumor ablation including radiofrequency ablation, microwave ablation, cryoablation and irreversible electroporation The results collected from this registry and the analyses generated will be valuable reference for physicians in choosing treatment strategy in the future.
|Study Type :||Observational|
|Estimated Enrollment :||500 participants|
|Official Title:||Eastern Ablation Registry for Solid Tumor (EAST)|
|Actual Study Start Date :||September 1, 2017|
|Estimated Primary Completion Date :||April 30, 2020|
|Estimated Study Completion Date :||April 30, 2020|
- Other: RFA, MWA, cryo and IRE
local tumor ablation
- To observe the efficacy of local tumor ablation [ Time Frame: through study completion, an average of 1 year ]Response rate (RR) to local tumor ablation
- The effect of local tumor ablation [ Time Frame: up to 3 years ]time-to-progression
- To observe the survival rate [ Time Frame: up to 3 years ]overall survival (OS)
- To observe the progression-free survival rate [ Time Frame: up to 3 years ]to observe the progression-free survival
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03362749
|Contact: Kai-Wen Huang, M.D. Ph.D||886-2-23123456 ext email@example.com|
|National Taiwan University Hospital||Recruiting|
|Contact: Kai-wen Huang, MD, PhD firstname.lastname@example.org|
|Principal Investigator:||Kai-Wen Huang, M.D. Ph.D||National Taiwan University Hospital|